Literature DB >> 29506128

Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms.

Maeve A Lowery1,2, Winston Wong1,3, Emmet J Jordan1, Jonathan W Lee1, Yelena Kemel4, Joseph Vijai4,5, Diana Mandelker6, Ahmet Zehir4,5, Marinela Capanu7, Erin Salo-Mullen4, Angela G Arnold4, Kenneth H Yu1,2,3, Anna M Varghese1,2,3, David P Kelsen1,2,3, Robin Brenner1,2, Erica Kaufmann1,2, Vignesh Ravichandran4,5, Semanti Mukherjee4, Michael F Berger5,6, David M Hyman1,5,3, David S Klimstra6, Ghassan K Abou-Alfa1,3, Catherine Tjan1, Christina Covington1, Hannah Maynard1, Peter J Allen2,8, Gokce Askan2,6, Steven D Leach2,8, Christine A Iacobuzio-Donahue2, Mark E Robson1,4, Kenneth Offit1,4, Zsofia K Stadler1,4,3, Eileen M O'Reilly1,2,3.   

Abstract

Background: Identification of pathogenic germline alterations (PGAs) has important clinical and therapeutic implications in pancreas cancer. We performed comprehensive germline testing (GT) in an unselected prospective cohort of patients with exocrine pancreatic neoplasms with genotype and phenotype association to facilitate identification of prognostic and/or predictive biomarkers and examine potential therapeutic implications.
Methods: Six hundred fifteen unselected patients with exocrine pancreatic neoplasms were prospectively consented for somatic tumor and matched sample profiling for 410-468 genes. GT for PGAs in 76 genes associated with cancer susceptibility was performed in an "identified" manner in 356 (57.9%) patients and in an "anonymized" manner in 259 (42.1%) patients, using an institutional review board-approved protocol. Detailed clinical and pathological features, response to platinum, and overall survival (OS) were collected for the identified cohort. OS was analyzed with Kaplan-Meier curves.
Results: PGAs were present in 122 (19.8%) of 615 patients involving 24 different genes, including BRCA1/2, ATM, PALB2, and multiple additional genes associated with the DNA damage response pathway. Of 122 patients with germline alterations, 41.8% did not meet current guidelines for GT. The difference in median OS was not statistically significant between patients with and without PGA (50.8 months, 95% confidence interval = 34.5 to not reached, two-sided P = .94). Loss of heterozygosity was found in 60.0% of BRCA1/2. Conclusions: PGAs frequently occur in pancreas exocrine neoplasms and involve multiple genes beyond those previously associated with hereditary pancreatic cancer. These PGAs are therapeutically actionable in about 5% to 10% of patients. These data support routinely offering GT in all pancreatic ductal adenocarcimona patients with a broad panel of known hereditary cancer predisposition genes.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29506128      PMCID: PMC6186514          DOI: 10.1093/jnci/djy024

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  29 in total

1.  Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification.

Authors:  Jan P Schouten; Cathal J McElgunn; Raymond Waaijer; Danny Zwijnenburg; Filip Diepvens; Gerard Pals
Journal:  Nucleic Acids Res       Date:  2002-06-15       Impact factor: 16.971

2.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data.

Authors:  Aaron McKenna; Matthew Hanna; Eric Banks; Andrey Sivachenko; Kristian Cibulskis; Andrew Kernytsky; Kiran Garimella; David Altshuler; Stacey Gabriel; Mark Daly; Mark A DePristo
Journal:  Genome Res       Date:  2010-07-19       Impact factor: 9.043

3.  FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing.

Authors:  Ronglai Shen; Venkatraman E Seshan
Journal:  Nucleic Acids Res       Date:  2016-06-07       Impact factor: 16.971

4.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.

Authors:  Lola Rahib; Benjamin D Smith; Rhonda Aizenberg; Allison B Rosenzweig; Julie M Fleshman; Lynn M Matrisian
Journal:  Cancer Res       Date:  2014-06-01       Impact factor: 12.701

5.  Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype.

Authors:  Maeve A Lowery; Emmet J Jordan; Olca Basturk; Ryan N Ptashkin; Ahmet Zehir; Michael F Berger; Tanisha Leach; Brian Herbst; Gokce Askan; Hannah Maynard; Danielle Glassman; Christina Covington; Nikolaus Schultz; Ghassan K Abou-Alfa; James J Harding; David S Klimstra; Jaclyn F Hechtman; David M Hyman; Peter J Allen; William R Jarnagin; Vinod P Balachandran; Anna M Varghese; Mark A Schattner; Kenneth H Yu; Leonard B Saltz; David B Solit; Christine A Iacobuzio-Donahue; Steven D Leach; Eileen M O'Reilly
Journal:  Clin Cancer Res       Date:  2017-07-28       Impact factor: 12.531

6.  Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas.

Authors:  M Goggins; M Schutte; J Lu; C A Moskaluk; C L Weinstein; G M Petersen; C J Yeo; C E Jackson; H T Lynch; R H Hruban; S E Kern
Journal:  Cancer Res       Date:  1996-12-01       Impact factor: 12.701

7.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

Authors:  Daniel D Von Hoff; Thomas Ervin; Francis P Arena; E Gabriela Chiorean; Jeffrey Infante; Malcolm Moore; Thomas Seay; Sergei A Tjulandin; Wen Wee Ma; Mansoor N Saleh; Marion Harris; Michele Reni; Scot Dowden; Daniel Laheru; Nathan Bahary; Ramesh K Ramanathan; Josep Tabernero; Manuel Hidalgo; David Goldstein; Eric Van Cutsem; Xinyu Wei; Jose Iglesias; Markus F Renschler
Journal:  N Engl J Med       Date:  2013-10-16       Impact factor: 91.245

8.  Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.

Authors:  Nuala McCabe; Nicholas C Turner; Christopher J Lord; Katarzyna Kluzek; Aneta Bialkowska; Sally Swift; Sabrina Giavara; Mark J O'Connor; Andrew N Tutt; Małgorzata Z Zdzienicka; Graeme C M Smith; Alan Ashworth
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

9.  Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

Authors:  Ahmet Zehir; Ryma Benayed; Ronak H Shah; Aijazuddin Syed; Sumit Middha; Hyunjae R Kim; Preethi Srinivasan; Jianjiong Gao; Debyani Chakravarty; Sean M Devlin; Matthew D Hellmann; David A Barron; Alison M Schram; Meera Hameed; Snjezana Dogan; Dara S Ross; Jaclyn F Hechtman; Deborah F DeLair; JinJuan Yao; Diana L Mandelker; Donavan T Cheng; Raghu Chandramohan; Abhinita S Mohanty; Ryan N Ptashkin; Gowtham Jayakumaran; Meera Prasad; Mustafa H Syed; Anoop Balakrishnan Rema; Zhen Y Liu; Khedoudja Nafa; Laetitia Borsu; Justyna Sadowska; Jacklyn Casanova; Ruben Bacares; Iwona J Kiecka; Anna Razumova; Julie B Son; Lisa Stewart; Tessara Baldi; Kerry A Mullaney; Hikmat Al-Ahmadie; Efsevia Vakiani; Adam A Abeshouse; Alexander V Penson; Philip Jonsson; Niedzica Camacho; Matthew T Chang; Helen H Won; Benjamin E Gross; Ritika Kundra; Zachary J Heins; Hsiao-Wei Chen; Sarah Phillips; Hongxin Zhang; Jiaojiao Wang; Angelica Ochoa; Jonathan Wills; Michael Eubank; Stacy B Thomas; Stuart M Gardos; Dalicia N Reales; Jesse Galle; Robert Durany; Roy Cambria; Wassim Abida; Andrea Cercek; Darren R Feldman; Mrinal M Gounder; A Ari Hakimi; James J Harding; Gopa Iyer; Yelena Y Janjigian; Emmet J Jordan; Ciara M Kelly; Maeve A Lowery; Luc G T Morris; Antonio M Omuro; Nitya Raj; Pedram Razavi; Alexander N Shoushtari; Neerav Shukla; Tara E Soumerai; Anna M Varghese; Rona Yaeger; Jonathan Coleman; Bernard Bochner; Gregory J Riely; Leonard B Saltz; Howard I Scher; Paul J Sabbatini; Mark E Robson; David S Klimstra; Barry S Taylor; Jose Baselga; Nikolaus Schultz; David M Hyman; Maria E Arcila; David B Solit; Marc Ladanyi; Michael F Berger
Journal:  Nat Med       Date:  2017-05-08       Impact factor: 53.440

10.  Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history.

Authors:  Kari G Chaffee; Ann L Oberg; Robert R McWilliams; Neil Majithia; Brian A Allen; John Kidd; Nanda Singh; Anne-Renee Hartman; Richard J Wenstrup; Gloria M Petersen
Journal:  Genet Med       Date:  2017-07-20       Impact factor: 8.822

View more
  58 in total

Review 1.  The pancreatic cancer genome revisited.

Authors:  Akimasa Hayashi; Jungeui Hong; Christine A Iacobuzio-Donahue
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-06-04       Impact factor: 46.802

2.  Ampullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes.

Authors:  Winston Wong; Maeve A Lowery; Michael F Berger; Yelena Kemel; Barry Taylor; Ahmet Zehir; Preethi Srinivasan; Chaitanya Bandlamudi; Joanne Chou; Marinela Capanu; Anna Varghese; Kenneth H Yu; Christine A Iacobuzio-Donahue; Jinru Shia; David S Klimstra; William R Jarnagin; Zsofia K Stadler; Eileen M O'Reilly
Journal:  Cancer       Date:  2019-01-08       Impact factor: 6.860

Review 3.  Genetic cancer predisposition syndromes among older adults.

Authors:  Yanin Chavarri-Guerra; Thomas P Slavin; Ossian Longoria-Lozano; Jeffrey N Weitzel
Journal:  J Geriatr Oncol       Date:  2020-01-21       Impact factor: 3.599

4.  Deleterious Germline Mutations Are a Risk Factor for Neoplastic Progression Among High-Risk Individuals Undergoing Pancreatic Surveillance.

Authors:  Toshiya Abe; Amanda L Blackford; Koji Tamura; Madeline Ford; Patrick McCormick; Miguel Chuidian; Jose Alejandro Almario; Michael Borges; Anne Marie Lennon; Eun Ji Shin; Alison P Klein; Ralph H Hruban; Marcia I Canto; Michael Goggins
Journal:  J Clin Oncol       Date:  2019-03-18       Impact factor: 44.544

5.  Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma.

Authors:  Evan J Walker; Julia Carnevale; Christina Pedley; Amie Blanco; Salina Chan; Eric A Collisson; Margaret A Tempero; Andrew H Ko
Journal:  Fam Cancer       Date:  2019-04       Impact factor: 2.375

6.  Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings.

Authors:  Hannah Maynard; Zsofia K Stadler; Michael F Berger; David B Solit; Michele Ly; Maeve A Lowery; Diana Mandelker; Liying Zhang; Emmett Jordan; Imane El Dika; Yelena Kemel; Marc Ladanyi; Mark E Robson; Eileen M O'Reilly; Ghassan K Abou-Alfa
Journal:  Cancer       Date:  2020-02-03       Impact factor: 6.860

7.  Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma.

Authors:  Allen S Ho; Angelica Ochoa; Gowtham Jayakumaran; Ahmet Zehir; Cristina Valero Mayor; Justin Tepe; Vladimir Makarov; Martin G Dalin; Jie He; Mark Bailey; Meagan Montesion; Jeffrey S Ross; Vincent A Miller; Lindsay Chan; Ian Ganly; Snjezana Dogan; Nora Katabi; Petros Tsipouras; Patrick Ha; Nishant Agrawal; David B Solit; P Andrew Futreal; Adel K El Naggar; Jorge S Reis-Filho; Britta Weigelt; Alan L Ho; Nikolaus Schultz; Timothy A Chan; Luc Gt Morris
Journal:  J Clin Invest       Date:  2019-10-01       Impact factor: 14.808

8.  Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection.

Authors:  Wungki Park; Jiapeng Chen; Nadeem Riaz; Eileen M O'Reilly; Joanne F Chou; Anna M Varghese; Kenneth H Yu; Winston Wong; Marinela Capanu; Vinod Balachandran; Caitlin A McIntyre; Imane El Dika; Danny N Khalil; James J Harding; Nima Ghalehsari; Zoe McKinnell; Sree B Chalasani; Vladimir Makarov; Pier Selenica; Xin Pei; Nicolas Lecomte; David P Kelsen; Ghassan K Abou-Alfa; Mark E Robson; Liying Zhang; Michael F Berger; Nikolaus Schultz; Timothy A Chan; Simon N Powell; Jorge S Reis-Filho; Christine A Iacobuzio-Donahue
Journal:  Clin Cancer Res       Date:  2020-05-22       Impact factor: 12.531

9.  Childhood-onset autosomal recessive ataxias: a cross-sectional study from Turkey.

Authors:  Hatice Mutlu-Albayrak; Emre Kırat; Gürkan Gürbüz
Journal:  Neurogenetics       Date:  2019-11-19       Impact factor: 2.660

10.  Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation.

Authors:  Eileen M O'Reilly; Jonathan W Lee; Mark Zalupski; Marinela Capanu; Jennifer Park; Talia Golan; Esther Tahover; Maeve A Lowery; Joanne F Chou; Vaibhav Sahai; Robin Brenner; Hedy L Kindler; Kenneth H Yu; Alice Zervoudakis; Shreya Vemuri; Zsofia K Stadler; Richard K G Do; Neesha Dhani; Alice P Chen; David P Kelsen
Journal:  J Clin Oncol       Date:  2020-01-24       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.